| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Purchases of property and equipment | NaN | 64,439 | NaN | 0 |
| Net cash used in investing activities | NaN | -64,439 | 0 | 0 |
| Non-cash interest expense | NaN | 0 | 0 | 0 |
| Merger transaction costs | NaN | 0 | 0 | 0 |
| Change in fair value of convertible promissory notes | NaN | 0 | 0 | 0 |
| Loss on series a preferred stock issuance | NaN | 0 | 0 | 0 |
| Loss on issuance of commitment shares | NaN | 0 | 0 | 0 |
| Issuance of written call option | NaN | NaN | 0 | 0 |
| Change in fair value of written call option derivative liabilities | NaN | NaN | 0 | 0 |
| Net loss | -5,446,255 | -4,677,580 | -5,726,812 | -15,871,040 |
| Depreciation expense | 30,268 | 58,061 | 518 | 131,994 |
| Stock-based compensation expense | 2,849,592 | 2,445,910 | 3,244,917 | 10,532,034 |
| Change in fair value of warrants | -25,831 | -3,295 | -64,959 | 7,553 |
| Amortization of right-of-use asset | 28,783 | 27,725 | 26,707 | 264,192 |
| Prepaid expenses and other assets | 341,597 | -91,299 | -308,302 | 297,763 |
| Other assets | 3 | 500,000 | 0 | -9,957 |
| Accounts payable | 458,472 | 28,196 | -1,032,371 | -959,943 |
| Accrued expenses and other liabilities | -258,417 | 376,143 | -379,140 | -71,206 |
| Operating lease liabilities | -28,781 | -27,726 | -26,706 | -243,544 |
| Net cash used in operating activities | -2,733,769 | -2,181,267 | -3,649,544 | -6,497,766 |
| Capital contribution | NaN | 0 | 1,000,000 | 2,500,000 |
| Cash acquired in connection with the reverse recapitalization | NaN | 0 | 0 | 0 |
| Proceeds from issuance of series a preferred stock | NaN | 0 | 0 | 0 |
| Proceeds from loan agreement | NaN | NaN | NaN | 3,400,000 |
| Proceeds from issuance of series c preferred stock | NaN | 0 | 0 | NaN |
| Nonrefundable prepaid proceeds towards anticipated series a-1 preferred stock issuance | NaN | 0 | 0 | 0 |
| Proceeds from loan agreement | NaN | 3,400,000 | NaN | NaN |
| Payment of offering costs associated with the sales agreement | NaN | 0 | 100,000 | NaN |
| Proceeds from loan agreement | -1,400,000 | NaN | 3,400,000 | NaN |
| Proceeds from issuance of shares under the sales agreement, net of offering costs | 873,702 | 1,760,984 | 3,101,409 | NaN |
| Net cash provided by financing activities | 2,873,702 | 1,760,984 | 4,001,409 | 5,900,000 |
| Net (decrease) increase in cash | NaN | -484,722 | NaN | NaN |
| Net increase in cash | 139,933 | -484,722 | 351,865 | -597,766 |
| Cash - beginning of period | 552,372 | 1,037,094 | 1,282,995 | NaN |
| Cash - end of period | 692,305 | 552,372 | 1,037,094 | NaN |
Tevogen Bio Holdings Inc. (TVGNW)
Tevogen Bio Holdings Inc. (TVGNW)